Purpose: The primary objective of this pilot study was to compare pain and function scores from patients before and after an ozone injection in combination with steroids and bupivacaine to treat herniated discs. A secondary objective was to correct some of the methodological weaknesses of some previously published ozone studies. Methods: Fifty patients were enrolled; 1-3 mL of 2 wt% ozone in 98 wt% oxygen was delivered into the nucleus pulposus, and 7-9 mL into the adjacent paravertebral tissues. The oxygen/ozone treatment was followed by a periganglionic injection of corticosteroid and bupivacaine. All patients were evaluated 1 month after the treatment to quantify improvement in pain and function, and to monitor for potential adverse events. Results: Forty-four patients had intradiscal injections and were included in the analysis. After 1 treatment, 75.0% showed significant improvement in pain based on the visual analog scale (improvement >1.8), 72.7% showed significant improvement in function based on the Oswestry disability index (improvement >15%), and 79.5% showed improvement based on the modified MacNab criteria. There were no adverse events associated with the treatment. Conclusions: Patients showed significant improvement in pain and function after receiving ozone injections in combination with steroids and bupivacaine for the treatment of herniated discs. Because of the lack of a control group and short follow-up times, conclusions about the safety and efficacy of ozone injections for the treatment of herniated discs are not warranted. However, the results provide sufficient evidence that the risk and expense of an additional randomized controlled study is merited. , nous ne sommes pas en mesure de formuler des conclusions au sujet de la s ecurit e et de l'efficacit e des injections d'ozone pour le traitement des hernies discales. Les r esultats permettent toutefois de justifier la tenue d'une autre etude clinique al eatoire en d epit des risques et des frais qui y sont associ es.
R esum e Objet : Cette etude pilote avait pour principal objectif de comparer les notes des patients a l' evaluation de la douleur et de la capacit e fonctionnelle avant et apr es le traitement de hernies discales par injection d'ozone en association avec des st ero€ ıdes et de la bupivaca€ ıne. Elle avait egalement comme objectif secondaire de corriger une partie des faiblesses m ethodologiques que pr esentaient certaines etudes sur l'ozone pr ec edemment publi ees. The mechanism of disc-related pain in the lumbar region is not fully understood, but is likely due to mechanical and/or inflammatory factors. The incidence of lumbar disc herniations in the American population is estimated to be 1%-2% for which approximately 200,000 lumbar discectomies are performed annually [1] . Since 1934, the accepted rationale for surgical treatment of disc herniations has been that lumbar back pain is a result of mechanical nerve compression and that surgical removal decreases mechanical compression, which relieves the pain [2, 3] .
Many common minimally invasive treatments such as percutaneous lumbar discectomy [4] , laser discectomy [5] , percutaneous plasma disc decompression (nucleoplasty) [6] , rely on the removal of disc material to reduce pressure on the ganglion nerve root. Others such as intradiscal electrothermal therapy (IDET) [7] and percutaneous intradiscal radiofrequency thermocoagulation (PIRT) [8] rely on fibrosis of the disc to diminish nerve root compression. The needles used by these devices to perform these procedures range in size from 8-17 gauge, and are sometimes difficult to deliver safely into the disc.
The safety and efficacy of oxygen/ozone injections through a 20-22 gauge needle has been reported in the literature and is summarized by a meta-analysis [9] , which quantifies the safety and effectiveness of ozone injections in herniated discs on pain and function. The primary objective of this pilot study was to compare pain and function scores from patients before and after an ozone plus steroid and bupivacaine injection to treat herniated discs. A secondary objective was to correct some of the methodological weaknesses of some previously published ozone studies. Specifically, Johnson [10] pointed out a lack of rigorous patient follow up and possible unintentional variation of ozone dose generation and delivery due to ozone generator inconsistencies. This clinical investigation was designed to specifically address these concerns through rigorous dose control and independently audited patient follow-up with well-validated back pain outcome scales.
Methods

Study Design
This prospective pilot study was designed as a singlecenter, single-arm clinical study. All patients were treated by Dr. Muto at A. Cardarelli Hospital in Naples, Italy, from October 2005 to March 2006. Institutional Review Board approval for this study, as well as registration of the study in a publicly available database, was not performed, or required, because the procedure being studied is regularly performed at the institution by Dr. Muto and was not considered experimental. The only difference between this study and the standard treatment was that we monitored the ozone concentration that was injected and performed patient follow-ups in which the patient's progress was recorded. Informed consent was obtained from each patient prior to his or her treatment. All other applicable guidelines of the Declaration of Helsinki [11] were followed in this study. Dr. Muto did not receive any additional compensation for the study. The study sponsor's only involvement was obtaining, tracking, and analysing patient outcome. No significant changes were made to the study design after study initiation.
Patient Selection
Fifty patients who met the exclusion/inclusion criteria described in Table 1 were enrolled for this study. Patients whose L5-S1 disc is not accessible. Disc accessibility may not be evident until the procedure is underway. Platelet count >50,000, INR <1.4, PTT <1.3, WBCC >12,000
Consecutive patients that met the exclusion/inclusion criteria were enrolled. Ninety people were screened to enroll 50 patients. Patients with single level contained herniated discs between 18-75 years of age with back pain and or radicular pain who were willing to undergo 1-month follow-up were enrolled. Forty patients failed screening because of prior surgery, multilevel disease, chronic degenerative change, scoliosis or anterolisthesis, >75% disc height loss, pregnancy or coagulopathy, infection, or cauda equina syndrome.
Ozone Generation and Measurement of Dose
Ozone was generated from a commercially available oxygen/ozone generator (Alnitec Ozo2; Alnitec, Futura, Italy). The concentration of the oxygen/ozone mixture produced by the generator was verified using a calibrated In-USA Mini Hi-Con UV ozone analyser (In-USA Inc, Salt Lake City, UT). Samples were taken and measured before and after every dose generation for each patient.
Technique for Oxygen/Ozone Injection
A sterile, 22-gauge, 15-cm-long Chiba needle (Cook Medical, Bloomington, IN) was inserted into the center of the disc from a paravertebral oblique approach under computed tomography (CT) guidance. A polypropylene 20 mL syringe was then filled with 10 mL of 2 wt% ozone in 98 wt% oxygen mixture and attached to the needle; 1-3 mL of the gas was injected into the disc, and the balance (7-9 mL) was then injected into the soft paravertebral tissues just outside the disc annulus. CT imaging was used to show the gas distribution after the intradiscal and paravertebral injections. Patients whose L5-S1 disc was not accessible were excluded from the analysis.
Following the oxygen/ozone injection, each patient received a 2 mL extradiscal injection containing 1 mL with 40 mg of Depo-Medrol and 1 mL of 0.25% of bupivacaine. Patients did not receive any antibiotics, or preoperation or postoperation medications. All patients were discharged on the same day as the treatment.
Methods to Assess Pain Relief
Visual analog scale (VAS) [12] , Oswestry Disability Index (ODI) [13] , and the modified MacNab criteria [14] questionnaires were used to assess patient pain and function before and after treatment. The metrics that were established to define significant improvement were: 1) an improvement 1.8 cm on the VAS (based on the minimum clinically important difference [MCID]) [15] ; 2) an improvement of 1 level or more on the modified MacNab criteria; and 3) an improvement 15% on the ODI (based on the minimum detectable change [MDC]) [16] . The MCID and MDC were set as the significant improvement level based on which metric was higher for the pain/function scale; thus the VAS used MCID while the ODI used the MDC.
Baseline questionnaires were done on the treatment day, prior to the treatment and follow-up questionnaires were done approximately 1 month following treatment. Missing follow-up scores and follow-up scores from patients that dropped out of the study for surgery were set equal to the baseline scores (ie, no improvement). If a patient required a second treatment due to lack of improvement or continued pain, an additional follow-up questionnaire was conducted 1 month after the second treatment. An independent clinical monitoring organization (Flohr Consultants, Bonn, Germany) audited our procedures, documentation, and patient follow up. No significant changes were made to the outcome questionnaires or follow-up schedules during the study.
Statistical Analysis
The primary endpoints of this study were changes in the pretreatment and 1-month posttreatment VAS, ODI, and modified MacNab scores of the patients. The null hypothesis for all of the primary endpoints was that the difference between the study population's mean 1-month posttreatment scores and the mean pretreatment scores is equal to the significant improvement scores noted previously (ie, m b e m 1 ¼ D 0 , where D 0 ¼ 1.8 VAS, 15 ODI, and 1 modified MacNab). A paired t test was performed to test the null hypotheses. Analyses were performed with JMP Software (SAS Institute, Inc, Cary, NC) version 8.0 and Microsoft Excel version 14.0.6129.5000 (Microsoft, Seattle, WA). Secondary analyses such as success rate of patients requiring a second treatment, comparison of improvement by treated disc level, comparison of improvement by gender, and descriptive statistics of various aspects of the patient population were also performed.
Results
Patient Information
Fifty patients ranging in age from 18-74 years with a mean age of 45 years were enrolled into this study. Thirtythree of the 50 patients (66%) were male and 17 of the 50 patients (34%) were female. Six of the 50 patients had inaccessible L5-S1 discs and thus were excluded from the analysis. Thirty-eight of the remaining 44 patients (86%) had only 1 treatment, while 6 of the 44 patients (14%) required a second treatment. Three of the 44 patients (7%) went on to surgery after the first treatment prior to completing the 1-month follow-up questionnaire. They had large herniations and no relief from the first intervention. One patient was lost to follow-up. Figure 1 summarizes the average pain and function metrics before and after intradiscal oxygen/ozone treatments for the 44 patients. After 1 treatment, it was shown that the patient population's mean VAS, ODI, and modified MacNab scores improved beyond the significant improvement scores (1.8 VAS, 15 ODI, and 1 modified MacNab), rejecting the null hypothesis for all endpoints (VAS P ¼ .00003, ODI P ¼ .0002, and modified MacNab P ¼ .003). In fact, results showed, with a .05 level of significance, that the mean patient population's improvement scores were 2.7 for VAS, 20 for ODI, and 1.2 for modified MacNab. Additionally, significant improvements were shown by 75.0% of the patients for the VAS scale (>1.8 points), 72.7% of the patients for the ODI scale (>15 points), and 79.5% of the patients for the modified MacNab criteria (1 point).
Primary Analysis
Secondary Analyses
Five of the 6 (83%) patients who received a second treatment improved for all 3 pain and function metrics after the second treatment. Figure 2 is a summary of the pain and function results for these patients. The first treatment, second treatment, and overall success rates for all 44 patients are summarized in Figure 3 .
It is interesting to note that 1 patient experienced a 50% reduction on the ODI scale at the 1-month follow-up, but had a very low initial score of 8. This initial low score did not allow us to see the minimum 15-point reduction for statistical significance that is dictated by the ODI. Thus we decided to evaluate statistics on patients that showed any improvement. Forty patients (90.9%) showed improvement in both the VAS and ODI and 35 patients (79.5%) showed improvement in the modified MacNab.
A comparison of improvement in pain and function by disc level and gender was also performed. Figure 4 shows the success rates based on disc level treated. Figure 5 summarizes the results based on gender. There was no statistical difference between male and female patients for both the 
Ozone Analyses
The average ozone concentration for the entire study was independently verified using a calibrated photometric (UV) ozone analyser. The ozone generator was consistent and reproducible, with an average ozone concentration of 1.99 wt % and a standard deviation of 0.06 wt%. CT imaging confirmed the presence of intradiscal and extradiscal gas after the treatment. Figure 6 shows a typical example of CT images confirming accurate needle placement and gas delivery to the disc of interest.
Complications
Adverse events were documented in the procedural case report forms after the procedure and at 1 month as per the study protocol. There were no adverse events associated with this 50patient study.
Discussion
Safety of Oxygen/Ozone Treatment
Oxygen/ozone treatment has been used extensively for relieving lower back pain. Our study confirms the results of a meta-analysis [9] performed on multiple studies equaling approximately 8,000 patients, in that there were no adverse events associated with ozone injections. In addition, Pellicano et al. [17] reported about the experience from a large group of Italian radiologists who had collectively treated 15 000 patients with oxygen/ozone therapy without any complications or collateral effects.
Concerns about the reliability of ozone generators in producing a consistent safe level of ozone have been expressed [10] . Our measurements from a separate calibrated ozone monitor showed that the average ozone concentration injected was 1.99 wt% and that the generator was reliable. However, there are some safety concerns in using this type of ozone generator. The gas is aspirated from the generator, through a septum, by a 10-20 cc syringe when using this ozone generator. The disadvantages of drawing ozone from the ozone generator into a syringe are: 1) there are leak opportunities between the device and syringe, possibly leading to precipitation of bronchospasm, acute asthmatic episodes, corneal irritation, nasal mucosal desiccation, and loss of sense of smell; and 2) practitioners can unintentionally or intentionally vary the volume and concentration. The development of a sealed, controlled system is therefore of importance.
Mechanism of Action
The mechanism of pain relief for this study is complicated because of the 4 treatments involved: intradiscal ozone injection, extradiscal ozone injection, extradiscal corticosteroid, and extradiscal bupivacaine. After extensive multilevel study in 9 Yucatan mini pigs in a good laboratory practice setting and analysis of the pathology in a good laboratory practice Food and Drug Administration-approved veterinary pathology lab we believe that the primary mechanism of action of the oxygen/ozone mixture is reduction in size of the herniated disc due to a redox reaction between the 03 and the glycosaminoglycans in the nucleus pulposis. This reduces the osmotic gradient across the end plates resulting in disc dehydration and volume reduction. This work is in submission to the Journal of Vascular and Interventional Radiology.
Volume reduction is also the primary mechanism of action for percutaneous plasma discectomy [18] . O'Neill et al. [18] also showed that discs treated via plasma discectomy exhibit a secondary mechanism of action for disc healing based on analgesic effects, The ozone decreases the disc pressure on the nerve via nucleus pulposus volume reduction and the steroid reduces inflammation in the paravertebral muscle adjacent to the disc.
Comparison With Other Treatment Options
The first treatment success rates for oxygen/ozone treatment from this study are similar to other minimally invasive treatments for contained lumbar disc herniations. However, oxygen/ozone treatment has the advantage that it is less invasive than surgical discectomy as well as most other minimally invasive percutaneous discectomy techniques (IDET, PIRT, nucleoplasty). Surgical discectomy has success rates ranging from 65%-92% [4, 19] . Laser discectomy studies report similar overall success rates, ranging from 70%-89% with slightly higher complication rates as 0.5% of patients included in the studies had an infection associated with the study [5, 20] . It is interesting that only 1 case of discitis has been reported after ozone therapy unlike all the other methods of disk volume reduction [21] . This is most likely due to the fact that ozone is a strong oxidizer and an excellent disinfecting agent [22] . The success rates for other minimally invasive techniques (IDET, PIRT, nucleoplasty) vary from 7.7%-83% depending on inclusion/exclusion criteria, patient follow-up, pain metrics, and type of clinical trial [6e8].
Epidural steroid injections alone for treatment of contained herniated lumbar intervertebral disc have success rates ranging from 51 to 80% depending on type of herniation, follow-up time, and whether image guidance is used to position the injection [23e25]. Bonnetti et al [26] compared the effectiveness of extradiscal ozone vs steroid injections for lower back pain. Oxygen/ozone treatment had a statistically significant long-term advantage over steroids and was highly effective in relieving acute and chronic lower back pain and sciatica. Gallucci et al [27] similarly found that ozone þ steroid þ anesthetic treatments are more effective (74%) than steroid þ anesthetic (47%) at a 6-month follow-up period using ODI patient questionnaire.
Limitations of the Study
This study was a pilot clinical trial designed to determine if the cost and risk of a more rigorous randomized-controlled study is warranted. Based on these results we will now proceed to a prospective randomized study.
Conclusions
This study showed that patients achieved significant improvement in VAS, ODI, and modified MacNab scales for pain and function, with no adverse events, after receiving ozone injections in combination with anesthetics and steroids for the treatment of herniated discs. Conclusions about the safety and efficacy, especially long term, of ozone injections for the treatment of herniated discs are not warranted by this study alone because of the lack of a control group and short follow-up times, and because anesthetic and steroids were injected with the ozone. The results do, however, provide sufficient evidence that the risk and expense of an additional randomized controlled study is merited.
